- News & Analysis
- Home
- Global Corporate Venturing
- Global University Venturing
- Latest News
- Publications
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- Video
- Subscribe
- Newsletters
- Events
Page 43
Aledade aligns with corporates to raise $100m
GV-backed Aledade has secured series D funding at a $2.2bn post-money valuation to build out the business model for its primary care network.
Jan 21, 2021Bloom & Wild makes room for $102m
Burda Principal Investments returned for a series D round that lifted flower delivery service Bloom & Wild's total funding to at least $130m.
Jan 18, 2021Sennder secures $160m in series D round
Existing investor Scania co-led a series D round in which the trucking services platform developer achieved a valuation above $1bn.
Jan 15, 2021Impulse Dynamics gets $60m implant
The Minth Group, Zoll Medical and Abiomed-backed medical device developer has raised at least $217m in total after closing additional series D funding.
Jan 15, 2021Rapyd wraps up $300m series D
The Stripe-backed cross-border payment platform developer more than doubled its valuation to $2.5bn in the Coatue-led round.
Jan 14, 2021M-Service embraces nine-figure series D round
The Standard Chartered-backed owner of digital wallet Momo will use the funding to launch its own strategic investment subsidiary.
Jan 14, 2021Workato serves up $110m series D
The Workday, Salesforce and ServiceNow-backed workflow automation software provider boosted its valuation to $1.7bn and its overall funding to over $220m.
Jan 13, 2021Komodo loads up on $44m
The McKesson-backed software provider secured $44m in series D funding alongside the acquisition of healthcare software developer Mavens.
Jan 12, 2021Mambu ambles to $135m round
The Commerzbank-backed financial services software provider's valuation now tops $2bn, TCV having led its latest round.
Jan 12, 2021Abbisko absorbs $123m in series D round
Lilly Asia Ventures, a regional corporate venturing subsidiary of pharmaceutical firm Eli Lilly, reinvested in a round set to accelerate development of Abbisko's cancer-focused drug candidates.
Jan 12, 2021
About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.